"In Vitro Diagnostics/IVD Market Projected to reach USD 78.74 billion by 2021, at a CAGR of
5.5% during the forecast period of 2016 to 2021" published in June 2017. It is a professional and
in-depth study.
Summary
Market Research Report Store announces a new report ＂In Vitro Diagnostics/IVD Market＂
added to its database.The global IVD market is projected to reach USD 78.74 billion by 2021, at a
CAGR of 5.5% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by
the increasing prevalence of diseases such as diabetes, cardiovascular diseases, and across the globe
and shift in focus from centralized laboratories to decentralized point-of-care testing is also support the
growth of the IVD market.
Detailed TOC Of Report @
https://www.marketresearchreportstore.com/
Ask a sample, click here [email protected]
In this report, the global IVD market is segmented by products & services, technology, application, end
user, and region. Based on technology, the IVD market is mainly segmented into
immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, clinical
microbiology, coagulation & hemostasis, and other technologies. The immunoassays/immunochemistry
segment accounted for the largest share of the IVD market in 2015. The growing preference for these
technologies in clinical diagnostics over conventional methods and the ability of
immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy
are contributing to the growth of immunoassays/immunochemistry market during forecast period.
Based on application, the market is segmented into diabetes, infectious diseases, oncology/cancer,
cardiology, HIV/AIDS, autoimmune diseases, nephrology, drug testing/pharmacogenomics, and other
applications. In 2015, the infectious diseases segment accounted for the largest share of the IVD market.
The oncology/cancer segment is expected to register the highest CAGR during the forecast period due
to the growing incidence of cancer forms that stimulates the demand for early detection of the disease.
In 2015, North America commanded the largest share of the IVD market, followed by Europe. The U.S.
is a prime market for IVD due to the rising acceptance of point-of-care diagnostics and patient
self-testing practices in the country. The Asia-Pacific market is expected to witness the highest growth
in the coming years primarily due to the growing focus of manufacturers on this region.
Major players in the global IVD market are Roche Diagnostics (Switzerland), Abbott Laboratories
(U.S.), Siemens Healthineers (Germany), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc.